SEC Tracker
Get the app

Revolution Medicines RVMD

Revolution Medicines secures $250M loan

Form
8-K
Filed
Importance
Routine
  1. FDA approved RASONQUE on Oct 8, 2026
  2. Tranche A Loan of $250M advanced on Oct 8, 2026
  3. Interest rate: 3-month SOFR + 5.75% with 3.50% floor

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Revolution Medicines files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
  2. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  3. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  4. Repligen RGEN public float $6.0B, Jun 30, 2025
  5. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025